LY3143921

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

CDC7 kinase inhibitor

Related drugs:

‹

›

TP53 mutation	Urothelial Cancer	TP53 mutation	Urothelial Cancer	LY3143921 Sensitive: C2 – Inclusion Criteria LY3143921 Sensitive : C2	LY3143921 Sensitive: C2 – Inclusion Criteria LY3143921 Sensitive : C2
TP53 mutation	Solid Tumor	TP53 mutation	Solid Tumor	LY3143921 Sensitive: C2 – Inclusion Criteria LY3143921 Sensitive : C2	LY3143921 Sensitive: C2 – Inclusion Criteria LY3143921 Sensitive : C2

Associations
(2)